Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection
- PMID: 9624467
- PMCID: PMC105595
- DOI: 10.1128/AAC.42.6.1319
Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection
Abstract
We conducted an in vivo study with the mouse model of Vibrio vulnificus infection to evaluate the efficacies of therapy with minocycline or cefotaxime alone and in combination. V. vulnificus was introduced subcutaneously into the area over the right thigh. The inoculum size ranged from 1.0 x 10(3) to 1.2 x 10(8) CFU from experiment to experiment but was constant for all animals in the same experiment. Antibiotics were given intraperitoneally 2 h after the bacteria were inoculated. In experiments 1 to 4, the standard dose for humans was used to treat the infection, while in experiment 5, five times the standard dose for humans was used to treat the infection. In experiment 1, with a small inoculum of 5 x 10(3) CFU, all mice in the saline-treated control group and the cefotaxime-, minocycline-, and combined antibiotic-treated groups survived. In experiment 2, with a moderate inoculum of 1.2 x 10(5) CFU, all the mice in the three antibiotic-treated groups survived, while only two of nine mice in the control group survived. In experiment 3, with a large inoculum of 8.0 x 10(7) CFU, six of nine mice in the combined antibiotic-treated group survived, while only one of nine mice in the cefotaxime-treated group and none of the mice in the control and minocycline-treated groups survived. In experiment 4, with a large inoculum of 1.2 x 10(8) CFU, 8 of 20 mice in the combined antibiotic-treated group survived, while none of the 20 mice in the control group, the group treated with cefotaxime alone, and the group treated with minocycline alone survived. In experiment 5, in which mice were infected with a large inoculum of 6.6 x 10(7) CFU and treated with five times the standard human dose of antibiotics, 10 of 12 mice in the combined antibiotic-treated group survived, while only 4 of 12 mice in the minocycline-treated group, 1 of 12 mice in the cefotaxime-treated group, and none of the mice in the control group survived. In experiments 3 to 5, the difference in the survival rates between the combined antibiotic-treated and minocycline-treated groups was statistically significant (P < 0.05). These results indicate that combination therapy with cefotaxime and minocycline is distinctly more advantageous than therapy with the single antibiotic regimen for the treatment of severe experimental V. vulnificus infections.
Similar articles
-
In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus.J Microbiol Immunol Infect. 2018 Feb;51(1):76-81. doi: 10.1016/j.jmii.2016.04.009. Epub 2016 May 13. J Microbiol Immunol Infect. 2018. PMID: 27260781
-
In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus.Antimicrob Agents Chemother. 2002 Nov;46(11):3580-4. doi: 10.1128/AAC.46.11.3580-3584.2002. Antimicrob Agents Chemother. 2002. PMID: 12384368 Free PMC article.
-
Synergistic antimicrobial effect of cefotaxime and minocycline on proinflammatory cytokine levels in a murine model of Vibrio vulnificus infection.J Microbiol Immunol Infect. 2007 Apr;40(2):123-33. J Microbiol Immunol Infect. 2007. PMID: 17446960
-
In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus.Antimicrob Agents Chemother. 1997 Oct;41(10):2214-7. doi: 10.1128/AAC.41.10.2214. Antimicrob Agents Chemother. 1997. PMID: 9333050 Free PMC article.
-
Vibrio vulnificus infection: clinical manifestations, pathogenesis, and antimicrobial therapy.J Microbiol Immunol Infect. 2003 Jun;36(2):81-8. J Microbiol Immunol Infect. 2003. PMID: 12886957 Review.
Cited by
-
Vibrio Vulnificus Necrotizing Fasciitis Associated with Acupuncture.Infect Dis Rep. 2015 Sep 29;7(3):5901. doi: 10.4081/idr.2015.5901. eCollection 2015 Aug 11. Infect Dis Rep. 2015. PMID: 26500738 Free PMC article.
-
In vitro and in vivo combinations of cefotaxime and minocycline against Aeromonas hydrophila.Antimicrob Agents Chemother. 2001 Apr;45(4):1281-3. doi: 10.1128/AAC.45.4.1281-1283.2001. Antimicrob Agents Chemother. 2001. PMID: 11257047 Free PMC article.
-
Optimizing tylosin dosage for co-infection of Actinobacillus pleuropneumoniae and Pasteurella multocida in pigs using pharmacokinetic/pharmacodynamic modeling.Front Pharmacol. 2023 Sep 22;14:1258403. doi: 10.3389/fphar.2023.1258403. eCollection 2023. Front Pharmacol. 2023. PMID: 37808183 Free PMC article.
-
Soft tissue infections caused by marine bacterial pathogens: epidemiology, diagnosis, and management.Curr Infect Dis Rep. 2011 Oct;13(5):470-7. doi: 10.1007/s11908-011-0199-3. Curr Infect Dis Rep. 2011. PMID: 21785929
-
Inoculum effect of antimicrobial peptides.Proc Natl Acad Sci U S A. 2021 May 25;118(21):e2014364118. doi: 10.1073/pnas.2014364118. Proc Natl Acad Sci U S A. 2021. PMID: 34021080 Free PMC article.
References
-
- Blake P A, Merson M H, Weaver R E, Hollis D G, Heublein P C. Disease caused by a marine Vibrio: clinical characteristics and epidemiology. N Engl J Med. 1979;300:1–5. - PubMed
-
- Bonner J R, Coker A S, Berryman C R, Pollock H M. Spectrum of vibrio infections in a Gulf Coast community. Ann Intern Med. 1983;99:464–469. - PubMed
-
- Bowdre J H, Hull J H, Cocchetto D M. Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline. J Pharmacol Exp Ther. 1983;225:595–598. - PubMed
-
- Chang J J, Sheen I S, Peng S M, Chen P C, Wu C S, Leu H S. Vibrio vulnificus infection: report of 8 cases and review of cases in Taiwan. Chang Gung Med J. 1994;17:339–345. - PubMed
-
- Chuang Y C, Young C, Chen C W. Vibrio vulnificus infection. Scand J Infect Dis. 1989;21:721–726. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources